{"id":915659,"date":"2025-12-03T10:16:22","date_gmt":"2025-12-03T15:16:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\/"},"modified":"2025-12-03T10:16:22","modified_gmt":"2025-12-03T15:16:22","slug":"protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\/","title":{"rendered":"Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">\n          <em>TARA-002 demonstrates 72% complete response rate at any time in BCG-Na\u00efve patients<\/em><\/p>\n<\/li>\n<li style=\"margin-bottom:8pt\">\n          <em>TARA-002 demonstrates a 69% complete response rate at the 6-month landmark and a 50% complete response rate at the 12-month landmark in BCG-Na\u00efve patients<\/em><\/p>\n<\/li>\n<li style=\"margin-bottom:8pt\">\n          <em>Favorable safety and tolerability profile observed with no Grade 3 or greater treatment-related adverse events reported<\/em><\/p>\n<\/li>\n<li style=\"margin-bottom:8pt\">\n          <em>Company obtained written feedback from FDA on registrational path forward for TARA-002 in BCG-Na\u00efve patients<\/em><\/p>\n<\/li>\n<li style=\"margin-bottom:8pt\">\n          <em>Company remains on track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in the registrational cohort of the ADVANCED-2 trial in Q1 2026 <\/em><\/p>\n<\/li>\n<li style=\"margin-bottom:8pt\">\n          <em>Company expects to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 2H 2026<\/em><\/p>\n<\/li>\n<li style=\"margin-bottom:8pt\">\n          <em>Company to host conference call and webcast today at 8:30 a.m. ET<\/em><\/p>\n<\/li>\n<\/ul>\n<p align=\"left\">NEW YORK, Dec.  03, 2025  (GLOBE NEWSWIRE) &#8212; Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced updated interim data from the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with carcinoma in situ or CIS (\u00b1 Ta\/T1) non-muscle invasive bladder cancer (NMIBC). These results in Bacillus Calmette-Gu\u00e9rin (BCG)-Na\u00efve NMIBC patients will be featured during a poster session at the 26th Annual Meeting of the Society of Urologic Oncology (SUO) in Phoenix, Arizona.<\/p>\n<p>\u201cThese positive results continue to support TARA-002\u2019s potential in the NMIBC treatment landscape, and we look forward to finalizing a regulatory pathway for TARA-002 in BCG-Na\u00efve patients,\u201d said\u00a0Jesse Shefferman, Chief Executive Officer of\u00a0Protara Therapeutics. \u201cWe remain on track to provide an update on the registrational BCG-Unresponsive patient cohort in the ADVANCED-2 trial in the first quarter of 2026 and expect to complete enrollment of this cohort in the second half of 2026.\u201d<\/p>\n<p>\u201cThese encouraging TARA-002 results demonstrate meaningful and durable activity in BCG-Na\u00efve NMIBC patients,\u201d said\u00a0Mark Tyson, M.D., MPH, Vice Chair for Research and a Professor in the Department of Urology with the Mayo Clinic in Phoenix, Arizona, and ADVANCED-2 study investigator. \u201cThe clinically meaningful response rates at six and 12 months, coupled with a favorable safety and tolerability profile and simple administration that is even more streamlined than BCG, make TARA-002 a compelling potential treatment option in the BCG-Na\u00efve setting.\u201d<\/p>\n<p>\n        <strong>Updated Interim Results<\/strong>\n      <\/p>\n<p>The dataset includes 31 BCG-Na\u00efve patients who received at least 1 dose of TARA-002; 29 patients completed at least one response assessment and were evaluable for efficacy as of a November 7, 2025\u00a0data cutoff. Patients received an induction course of six weekly intravesical instillations of TARA-002, followed by a maintenance course of three weekly instillations every three months. Re-induction was permitted for eligible patients with residual CIS and\/or recurrent high-grade Ta disease. Complete response (CR) rates at the six months and 12 months landmark time points include all participants who were either evaluable at that time point or had experienced disease progression or treatment failure prior to the scheduled visit.<\/p>\n<ul type=\"disc\">\n<li>The CR rate at any time was 72% (21\/29).<\/li>\n<li>The CR rate was 69% (18\/26) at six months and 50% (7\/14) at 12 months.<\/li>\n<li>Among initial responders, 88% (14\/16) maintained their response through six months and 100% (3\/3) through 12 months.<\/li>\n<li>Re-induction therapy successfully salvaged most initial non-responders, resulting in high conversion rates and durable responses: 80% (4\/5) of re-induced patients converted to a CR at 6 months, and 100% (4\/4) of those responders maintained their CR at 12 months.<\/li>\n<\/ul>\n<p>\n        <em>Safety and Tolerability<\/em>\n      <\/p>\n<p>The majority of treatment-related adverse events (TRAEs) were Grade 1 and transient with no Grade 3 or greater TRAEs as assessed by study investigators. No patients discontinued treatment due to TRAEs. The most commonly occurring TRAEs were dysuria (13%), fatigue (13%), and hematuria (6%).<\/p>\n<p>\n        <strong>Regulatory Update<\/strong>\n      <\/p>\n<p>The Company remains in ongoing dialogue with the U.S. Food and Drug Administration (FDA) on an expansion of the agreed upon registrational path forward for TARA-002 beyond the BCG-Unresponsive NMIBC patient population. The FDA has provided written feedback supporting a registrational design for a controlled trial in BCG-Na\u00efve patients (who have never been exposed and those who have not received BCG within the last 24 months and are ineligible to receive BCG or contraindicated, cannot tolerate BCG, do not have access to BCG, or refuse BCG). The FDA has agreed that BCG is not required as a comparator and that intravesical chemotherapy is an acceptable comparator to TARA-002 in BCG-Na\u00efve patients. The FDA also is aligned with the primary endpoint of the trial as the CR rate at month 6 with duration of response as a key secondary endpoint. The Company has engaged the FDA to determine how to include BCG-Exposed patients in its clinical trials of TARA-002, for whom no FDA-approved treatments are available and who have limited options to access investigational treatment through clinical trials.<\/p>\n<p>\n        <strong>About ADVANCED-2<\/strong>\n      <\/p>\n<p>ADVANCED-2 (NCT05951179) is a\u00a0Phase 2\u00a0open-label trial assessing intravesical TARA-002 in NMIBC patients with carcinoma in situ or CIS (\u00b1 Ta\/T1) who are Bacillus Calmette-Gu\u00e9rin (BCG)-Unresponsive (Cohort B N=75-100) or BCG-Na\u00efve (Cohort A N=31). Trial subjects received an induction course, with or without a reinduction, of six weekly intravesical instillations of TARA-002, followed by a maintenance course of three weekly instillations every three months.<\/p>\n<p>The Company remains on track to report interim results from approximately 25 six-month evaluable NMIBC patients from ADVANCED-2 with carcinoma in situ or CIS (\u00b1 Ta\/T1) who are BCG-Unresponsive in the first quarter of 2026 and expects to complete enrollment in this cohort in the second half of 2026.<\/p>\n<p>\n        <strong>Conference Call and Webcast<\/strong>\n      <\/p>\n<p>Protara will host a conference call and webcast today at 8:30 am ET to review the data reported this morning. The live event and accompanying slides can be accessed by visiting <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OYHwzrt-fmdCNKj2QSNtmMwVUGPgflzJt36ZwxQhWWQVUQ3jkETz-Gw779LH_ve-_NaEUjFZzl78QKaYFzYaXit0QlkoioTzWuuOb8Att4w3OVgmW9D-CjmQOFV7_sB8AErT5WGx19Vgkz8hC0lNJNMg5FI5hQLHOQk_TLHHfvaTBTBGlseV0IenarLT814vqw8HIDpS6F8-VHZgpEdMat75B6ts6BJaRiF6Hu_IFsnv-YIH4BYTlV6CAnduBlcJ\" rel=\"nofollow\" target=\"_blank\">https:\/\/protara-therapeutics-suo-update-call.open-exchange.net\/registration<\/a>, or via the Events and Presentations section of the Company\u2019s website: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OYHwzrt-fmdCNKj2QSNtmLbS1vJM6t6U085tqMPTYNIZ809LukOPDEbpceF6ShRLEB-GMgvWoinHG4iOVhKr38xu6c5neiF2dzeFxWWQoxE=\" rel=\"nofollow\" target=\"_blank\">https:\/\/ir.protaratx.com<\/a>. A replay of the webcast will be archived for a limited time following the event.<\/p>\n<p>\n        <strong>About TARA-002<\/strong>\n      <\/p>\n<p>TARA-002 is an investigational cell therapy in development for the treatment of NMIBC and of LMs, for which it has been granted Rare Pediatric Disease Designation by the\u00a0U.S. Food and Drug Administration. TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432, a broad immunopotentiator marketed as Picibanil\u00ae in\u00a0Japan\u00a0by Chugai Pharmaceutical Co., Ltd. Protara has successfully shown manufacturing comparability between TARA-002 and OK-432.<\/p>\n<p>TARA-002 is a first-in-class TLR2\/NOD2 agonist and novel immunopotentiator derived from inactivated Streptococcus pyogenes with a mechanism of action that includes the activation of innate and adaptive immune pathways within the bladder wall. When TARA-002 is administered, it is hypothesized that innate and adaptive immune cells within the cyst or tumor are activated and produce a pro-inflammatory response with release of cytokines such as tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma IL-6, IL-10, IL-12. TARA-002 also directly kills tumor cells and triggers a host immune response by inducing immunogenic cell death, which further enhances the antitumor immune response.<\/p>\n<p>\n        <strong>About Non-Muscle Invasive Bladder Cancer (NMIBC)<\/strong>\n      <\/p>\n<p>Bladder cancer is the sixth most common cancer in\u00a0the\u00a0United States, with NMIBC representing approximately 80% of bladder cancer diagnoses. Approximately 65,000 patients are diagnosed with NMIBC in\u00a0the United States\u00a0each year. NMIBC is cancer found in the tissue that lines the inner surface of the bladder that has not spread into the bladder muscle<\/p>\n<p>\n        <strong>About\u00a0Protara Therapeutics, Inc.<\/strong>\n      <\/p>\n<p>Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara\u2019s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing\u00a0Phase 2\u00a0trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or na\u00efve to treatment with Bacillus Calmette-Gu\u00e9rin, as well as a\u00a0Phase 2\u00a0trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OLTJB0E5c9nlLF3upSiyjVqKrjvnnYsXjYViM_z8ey2B8xUiB5K5ijTORVKYznOEvDLGcnQolPvskd3-qtnWBkQ8HayH8fo94eLhFbUtAzn8LKCQXh3Mn1aL1bB2wbdlVh_3CmzGBEuDhPQcFd0UOZCFWekJHf-XdU3Etx-fCdHJ0W-tX2nOjRxdU4OxsHHFepuFnSfsHV6ReOPB4m-Mf3BULQUkKuqk0PzWkzHmW2OewK6zBLOifo0Y6E33qsnS8kTvfYoVONC_WBKqcwTTFw4pAvr5z5StOuVXvyH1ElBLvc4EXXs3FrCyehBFeai_IAXGOTwD_V6mvPUW6tMxrQpJl_WlRIWTFK8a4i5EMa29qzzgIzkAe3ko6_0L8UhGi-iIteDew2NzDixRohTU-w8wcMBTLBdNSb59NK8OpKAMA44DdEZShd4Ig8I8CADzBoWarSAjnVRy1cJ0u3oD8JV8XsbaOoZIRvkt0BGpl14=\" rel=\"nofollow\" target=\"_blank\">www.protaratx.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>Statements contained in this press release regarding matters that are not historical facts are &#8220;forward looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some cases, use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201cproposed,\u201d \u201ccontinue,\u201d \u201cdesigned,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould\u201d or other words or expressions referencing future events, conditions or circumstances that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include but are not limited to, statements regarding Protara\u2019s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: Protara\u2019s business strategy, including its development plans for its product candidates and plans regarding the timing or outcome of existing or future clinical trials (including the timing of any particular phases of such trials and the timing of the announcement of any data produced during such trials or phases thereof); statements related to expectations regarding interactions with the\u00a0U.S. Food and Drug Administration\u00a0(FDA); Protara\u2019s financial position; statements regarding the anticipated safety or efficacy of Protara\u2019s product candidates; and Protara\u2019s outlook for the remainder of the year and future periods. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that contribute to the uncertain nature of the forward-looking statements include: risks that Protara\u2019s financial guidance may not be as expected, as well as risks and uncertainties associated with: Protara\u2019s development programs, including the initiation and completion of non-clinical studies and clinical trials and the timing of required filings with the FDA and other regulatory agencies; general market conditions; changes in the competitive landscape; changes in Protara\u2019s strategic and commercial plans; Protara\u2019s ability to obtain sufficient financing to fund its strategic plans and commercialization efforts; having to use cash in ways or on timing other than expected; the impact of market volatility on cash reserves; failure to attract and retain management and key personnel; the impact of general\u00a0U.S.\u00a0and foreign, economic, industry, market, regulatory, political or public health conditions; and the risks and uncertainties associated with Protara\u2019s business and financial condition in general, including the risks and uncertainties described more fully under the caption \u201cRisk Factors\u201d and elsewhere in Protara&#8217;s filings and reports with the\u00a0United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management&#8217;s assumptions and estimates as of such date. Protara undertakes no obligation to update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as required by law.<\/p>\n<p>\n        <strong>Company Contact:<\/strong>\n      <\/p>\n<p>Justine O&#8217;Malley<br \/>Protara Therapeutics<br \/>Justine.OMalley@protaratx.com<br \/>646-817-2836<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTg5OSM3MzAzMjg2IzIxODk3Njg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OWMzMWMyZGEtZDI4NC00NTE0LTg0MWMtNmJjMDJlMzYyZmI2LTEyMDEzMjEtMjAyNS0xMi0wMy1lbg==\/tiny\/Protara-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TARA-002 demonstrates 72% complete response rate at any time in BCG-Na\u00efve patients TARA-002 demonstrates a 69% complete response rate at the 6-month landmark and a 50% complete response rate at the 12-month landmark in BCG-Na\u00efve patients Favorable safety and tolerability profile observed with no Grade 3 or greater treatment-related adverse events reported Company obtained written feedback from FDA on registrational path forward for TARA-002 in BCG-Na\u00efve patients Company remains on track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in the registrational cohort of the ADVANCED-2 trial in Q1 2026 Company expects to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 2H 2026 Company to host conference call and webcast today at 8:30 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-915659","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TARA-002 demonstrates 72% complete response rate at any time in BCG-Na\u00efve patients TARA-002 demonstrates a 69% complete response rate at the 6-month landmark and a 50% complete response rate at the 12-month landmark in BCG-Na\u00efve patients Favorable safety and tolerability profile observed with no Grade 3 or greater treatment-related adverse events reported Company obtained written feedback from FDA on registrational path forward for TARA-002 in BCG-Na\u00efve patients Company remains on track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in the registrational cohort of the ADVANCED-2 trial in Q1 2026 Company expects to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 2H 2026 Company to host conference call and webcast today at 8:30 &hellip; Continue reading &quot;Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-03T15:16:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTg5OSM3MzAzMjg2IzIxODk3Njg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients\",\"datePublished\":\"2025-12-03T15:16:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\\\/\"},\"wordCount\":1797,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTg5OSM3MzAzMjg2IzIxODk3Njg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\\\/\",\"name\":\"Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTg5OSM3MzAzMjg2IzIxODk3Njg=\",\"datePublished\":\"2025-12-03T15:16:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTg5OSM3MzAzMjg2IzIxODk3Njg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTg5OSM3MzAzMjg2IzIxODk3Njg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\/","og_locale":"en_US","og_type":"article","og_title":"Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients - Market Newsdesk","og_description":"TARA-002 demonstrates 72% complete response rate at any time in BCG-Na\u00efve patients TARA-002 demonstrates a 69% complete response rate at the 6-month landmark and a 50% complete response rate at the 12-month landmark in BCG-Na\u00efve patients Favorable safety and tolerability profile observed with no Grade 3 or greater treatment-related adverse events reported Company obtained written feedback from FDA on registrational path forward for TARA-002 in BCG-Na\u00efve patients Company remains on track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in the registrational cohort of the ADVANCED-2 trial in Q1 2026 Company expects to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 2H 2026 Company to host conference call and webcast today at 8:30 &hellip; Continue reading \"Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-03T15:16:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTg5OSM3MzAzMjg2IzIxODk3Njg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients","datePublished":"2025-12-03T15:16:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\/"},"wordCount":1797,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTg5OSM3MzAzMjg2IzIxODk3Njg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\/","name":"Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTg5OSM3MzAzMjg2IzIxODk3Njg=","datePublished":"2025-12-03T15:16:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTg5OSM3MzAzMjg2IzIxODk3Njg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTg5OSM3MzAzMjg2IzIxODk3Njg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-announces-updated-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915659","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=915659"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915659\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=915659"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=915659"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=915659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}